✦ LIBER ✦
400 Ganciclovir-Resistant (GCV-R) CMV Is Common among Lung Transplant Recipients (LTR) Receiving Alemtuzumab Induction and Valganciclovir Prophylaxis (VGC px), and Treatment with Foscarnet (FOS) Is Both Ineffective and Toxic
✍ Scribed by L. Minces; C.J. Clancy; R.K. Shields; E.J. Kwak; F. Silveira; Y. Toyoda; C. Bermudez; J. Pilewski; M. Crespo; M.H. Nguyen
- Book ID
- 116524055
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 138 KB
- Volume
- 31
- Category
- Article
- ISSN
- 1557-3117
No coin nor oath required. For personal study only.